Illumina, Inc.
Illumina Announces New Credit Agreement
Summary
On June 17, 2024, Illumina, Inc. entered into a 364-day delayed draw credit agreement providing for a senior unsecured term loan credit facility of up to $750 million. The proceeds of the loans may be used to fund cash to the balance sheet of GRAIL, LLC, in connection with Illumina's planned divestment of GRAIL. The Credit Facility contains financial and operating covenants and is expected to be drawn in full on June 20, 2024, with a maturity date of June 19, 2025.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement